NCT01926626View on ClinicalTrials.gov

Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2014

Conditions
Nicotine Dependence
Interventions
DRUG

Nicotine Patch

"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"

DRUG

Moclobemide

"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"

Trial Locations (3)

27103

Duke Center for Smoking Cessation, Winston-Salem

27705

Duke Center forSmoking Cessation, Durham

28210

Duke Center for Smoking Cessation, Charlotte

All Listed Sponsors
collaborator

Philip Morris USA, Inc.

INDUSTRY

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Jed E. Rose

OTHER

NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers | Biotech Hunter | Biotech Hunter